+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Eculizumab Market - Global Forecast 2026-2032- Product Image
Eculizumab Market - Global Forecast 2026-2032- Product Image
Sale

Eculizumab Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118475
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Eculizumab Market is projected to reach USD 4.53 Billion in 2026. It is expected to continue growing at a CAGR of 5.19%, reaching USD 6.21 Billion by 2032.

Eculizumab Market: Executive Overview

Eculizumab is a targeted complement C5 inhibitor used in rare, potentially life-threatening disorders, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder in approved settings. Its clinical value is closely linked to sustained complement suppression, specialist diagnosis, infection prevention, and long-term treatment monitoring. Market development is shaped by regulatory decisions, evidence generation, patient identification, reimbursement, and competition from other complement-directed approaches.

Specialty Care and Access Are Reshaping Eculizumab Use

The treatment landscape is shifting toward earlier recognition of rare diseases, multidisciplinary care, and more structured use of biomarkers and diagnostic pathways. Infusion logistics, vaccination requirements, antimicrobial risk management, and continuity of treatment remain central operational considerations. Health systems are also evaluating treatment durability, administration burden, total care costs, and the role of longer-interval or alternative complement therapies. These changes favor providers that can coordinate diagnosis, specialty pharmacy or hospital supply, patient monitoring, and emergency-care protocols.

Artificial Intelligence Improves Diagnosis, Monitoring, and Evidence Generation

Artificial intelligence can support rare-disease identification by screening clinical records for patterns such as hemolysis, renal injury, thrombosis, cytopenias, or unexplained neuromuscular symptoms. It may also help prioritize confirmatory testing, identify patients at risk of breakthrough disease activity, and improve adverse-event surveillance. Additional applications include clinical-trial recruitment, real-world evidence analysis, infusion scheduling, and patient-support personalization. Human oversight remains essential because datasets may be incomplete, disease prevalence is low, and treatment decisions require specialist interpretation and validated clinical evidence.

Regional Insights: Uneven Diagnosis and Reimbursement Shape Adoption

North America generally benefits from advanced rare-disease infrastructure, specialist centers, and established reimbursement pathways, although prior authorization and affordability remain important considerations. Europe combines strong clinical networks with country-level variation in health technology assessment, procurement, and access rules. Asia-Pacific presents expanding diagnostic capacity alongside substantial differences in specialist availability, regulatory processes, and public coverage. Latin America is influenced by centralized purchasing, budget constraints, and uneven access to confirmatory testing. The Middle East is developing specialist and tertiary-care capabilities, while coverage and referral concentration vary across countries. Africa faces the greatest challenges in disease recognition, laboratory capacity, specialist access, and sustainable financing, making partnerships and referral networks particularly important.

Group Insights: Cooperation and Policy Alignment Remain Uneven

ASEAN markets show differing levels of regulatory maturity, reimbursement, and rare-disease infrastructure, making regional coordination valuable for diagnosis and referral. BRICS countries combine significant clinical capacity with wide internal variation in public coverage, procurement, and access to specialist care. The European Union benefits from cross-border scientific collaboration, but national reimbursement decisions continue to determine practical availability. G7 countries typically have robust research and specialist systems, while cost-effectiveness review and treatment eligibility remain key considerations. GCC states often possess concentrated tertiary-care capacity and can support centralized rare-disease programs. NATO members span diverse health systems, so military and civilian medical cooperation may assist preparedness, referral, and specialist knowledge exchange without eliminating national access differences.

Country Insights: National Systems Determine Practical Patient Access

Australia relies on specialist referral pathways and public reimbursement structures, with geography influencing access to treatment centers. Brazil combines advanced tertiary expertise with regional disparities in diagnosis and public-system availability. Canada’s provincial organization creates variation in reimbursement and referral processes. China is expanding rare-disease recognition and specialist capacity while navigating substantial regional differences. France, Germany, Italy, Spain, and the United Kingdom have established specialist networks, but national assessment, procurement, and budget-management approaches differ. India faces major variation between metropolitan centers and underserved areas, with affordability and diagnosis remaining central issues. Japan and South Korea have sophisticated healthcare systems and rare-disease programs, alongside detailed regulatory and reimbursement requirements. Mexico continues to develop specialized access amid regional and financing disparities. Russia’s access is influenced by public procurement, specialist concentration, and broader health-system conditions.

Strategic Priorities for Eculizumab Industry Leaders

Industry leaders should strengthen evidence across approved indications, with particular attention to long-term outcomes, treatment persistence, breakthrough disease activity, safety monitoring, and patient-relevant endpoints. They should support earlier diagnosis through clinician education, referral algorithms, validated testing pathways, and collaboration with rare-disease organizations. Access strategies should be tailored to national reimbursement and procurement systems rather than treated as globally uniform. Operationally, stakeholders should reinforce vaccination and infection-risk protocols, infusion-center readiness, supply continuity, and transparent patient-support services. Artificial intelligence should be deployed selectively with privacy controls, clinical validation, bias monitoring, and clear accountability. Partnerships with specialist centers and health authorities can improve registry quality and equitable referral.

Research Methodology: Evidence-Led Synthesis Without Market Forecasting

This executive summary uses the specified eculizumab market scope and synthesizes established clinical, regulatory, healthcare-delivery, and policy considerations. The analysis is organized across therapeutic evolution, artificial-intelligence applications, regional systems, economic and political groupings, and named countries. Insights are framed qualitatively and avoid market estimates, market sizing, market shares, forecasts, and unsupported commercial claims. Interpretation should be validated against current product labels, regulatory communications, clinical guidelines, peer-reviewed evidence, reimbursement decisions, procurement rules, and local public-health requirements before operational use.

Conclusion: Sustainable Value Depends on Diagnosis, Safety, and Access

Eculizumab remains a specialized therapy whose impact depends on accurately identifying eligible patients, initiating treatment through capable centers, and maintaining rigorous infection-risk and disease-activity monitoring. The next phase of market development will be determined less by clinical efficacy alone than by diagnostic reach, reimbursement design, treatment logistics, evidence quality, and responsible use of digital tools. Leaders that align clinical education, health-system partnerships, patient protection, and country-specific access strategies will be best positioned to support appropriate and sustainable use across diverse healthcare environments.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Eculizumab Market, by Indication
7.1. Introduction
7.2. Atypical Hemolytic Uremic Syndrome
7.2.1. First Line
7.2.2. Second Line
7.3. Generalized Myasthenia Gravis
7.3.1. Non-Refractory
7.3.2. Refractory
7.4. Neuromyelitis Optica Spectrum Disorder
7.4.1. Non-Refractory
7.4.2. Refractory
7.5. Paroxysmal Nocturnal Hemoglobinuria
7.5.1. First Line
7.5.2. Second Line
8. Eculizumab Market, by Distribution Channel
8.1. Introduction
8.2. Online
8.3. Offline
9. Eculizumab Market, by End User
9.1. Introduction
9.2. Hospitals
9.2.1. Secondary Hospitals
9.2.2. Tertiary Hospitals
9.3. Specialty Clinics
9.3.1. Hematology Clinics
9.3.2. Neurology Clinics
10. Eculizumab Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Pediatric
10.4. Geriatric
11. Eculizumab Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Eculizumab Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Eculizumab Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Alexion Pharmaceuticals, Inc.
15.3. Amgen Inc.
15.4. Apellis Pharmaceuticals, Inc.
15.5. AstraZeneca PLC
15.6. Biogen Inc.
15.7. Boehringer Ingelheim International GmbH
15.8. Bristol Myers Squibb Company
15.9. Catalyst Biosciences, Inc.
15.10. Celltrion Inc.
15.11. Janssen Pharmaceuticals, Inc.
15.12. Merck & Co., Inc.
15.13. Novartis AG
15.14. Pfizer Inc.
15.15. Regeneron Pharmaceuticals, Inc.
15.16. Roche Holding AG
15.17. Samsung Bioepis Co., Ltd.
15.18. Sanofi SA
15.19. Swedish Orphan Biovitrum AB
15.20. UCB S.A.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Eculizumab Market, Years Considered for the Study
FIGURE 2. Global Eculizumab Market, Research Design
FIGURE 3. Global Eculizumab Market, Research Framework
FIGURE 4. Global Eculizumab Market, Data Triangulation
FIGURE 5. Global Eculizumab Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Eculizumab Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Eculizumab Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Eculizumab Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 9. Global Eculizumab Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Eculizumab Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Eculizumab Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Eculizumab Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Eculizumab Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Eculizumab Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Eculizumab Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Eculizumab Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Eculizumab Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Eculizumab Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Eculizumab Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Eculizumab Market Segmentation & Coverage
TABLE 2. Global Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 3. Global Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Atypical Hemolytic Uremic Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Atypical Hemolytic Uremic Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Atypical Hemolytic Uremic Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Generalized Myasthenia Gravis Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Generalized Myasthenia Gravis Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Generalized Myasthenia Gravis Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Non-Refractory Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Non-Refractory Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Non-Refractory Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Refractory Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Refractory Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Refractory Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Neuromyelitis Optica Spectrum Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Neuromyelitis Optica Spectrum Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Neuromyelitis Optica Spectrum Disorder Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Non-Refractory Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Non-Refractory Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Non-Refractory Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Refractory Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Refractory Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Refractory Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Paroxysmal Nocturnal Hemoglobinuria Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Paroxysmal Nocturnal Hemoglobinuria Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Paroxysmal Nocturnal Hemoglobinuria Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 41. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 48. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Secondary Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Secondary Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Secondary Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Tertiary Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Tertiary Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Tertiary Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Hematology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Hematology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Hematology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Neurology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Neurology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Neurology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 67. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 88. North America Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. North America Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 90. North America Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 91. North America Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 92. North America Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 93. North America Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 94. North America Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. North America Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. North America Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 97. North America Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 98. North America Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 99. Latin America Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Latin America Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. Latin America Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 102. Latin America Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 103. Latin America Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 104. Latin America Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 105. Latin America Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Latin America Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Latin America Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 108. Latin America Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 109. Latin America Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 110. Europe Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Europe Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. Europe Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 113. Europe Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 114. Europe Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 115. Europe Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 116. Europe Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Europe Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. Europe Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 119. Europe Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 120. Europe Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 121. Middle East Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Middle East Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. Middle East Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 124. Middle East Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 125. Middle East Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 126. Middle East Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 127. Middle East Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. Middle East Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Middle East Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 130. Middle East Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 131. Middle East Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 132. Africa Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Africa Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. Africa Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 135. Africa Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 136. Africa Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 137. Africa Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 138. Africa Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. Africa Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Africa Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 141. Africa Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 142. Africa Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 143. Global Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. ASEAN Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. ASEAN Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 146. ASEAN Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 147. ASEAN Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 148. ASEAN Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 149. ASEAN Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 150. ASEAN Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. ASEAN Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. ASEAN Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 153. ASEAN Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 154. ASEAN Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 155. GCC Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. GCC Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 157. GCC Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 158. GCC Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 159. GCC Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 160. GCC Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 161. GCC Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. GCC Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. GCC Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 164. GCC Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 165. GCC Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 166. European Union Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. European Union Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 168. European Union Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 169. European Union Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 170. European Union Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 171. European Union Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 172. European Union Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. European Union Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. European Union Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 175. European Union Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 176. European Union Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 177. BRICS Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. BRICS Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. BRICS Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 180. BRICS Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 181. BRICS Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 182. BRICS Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 183. BRICS Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. BRICS Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. BRICS Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 186. BRICS Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 187. BRICS Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 188. G7 Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. G7 Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 190. G7 Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 191. G7 Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 192. G7 Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 193. G7 Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 194. G7 Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. G7 Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. G7 Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 197. G7 Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 198. G7 Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 199. NATO Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. NATO Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. NATO Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 202. NATO Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 203. NATO Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 204. NATO Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 205. NATO Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. NATO Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. NATO Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 208. NATO Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 209. NATO Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 210. Global Eculizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 211. United States Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 212. United States Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. United States Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 214. United States Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 215. United States Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 216. United States Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 217. United States Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. United States Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. United States Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 220. United States Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 221. United States Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 222. Canada Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 223. Canada Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. Canada Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 225. Canada Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 226. Canada Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 227. Canada Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 228. Canada Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Canada Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. Canada Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 231. Canada Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 232. Canada Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 233. Mexico Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 234. Mexico Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 235. Mexico Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 236. Mexico Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 237. Mexico Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 238. Mexico Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 239. Mexico Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. Mexico Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. Mexico Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 242. Mexico Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 243. Mexico Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 244. Brazil Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 245. Brazil Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 246. Brazil Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 247. Brazil Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 248. Brazil Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 249. Brazil Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 250. Brazil Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Brazil Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. Brazil Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 253. Brazil Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 254. Brazil Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 255. United Kingdom Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 256. United Kingdom Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 257. United Kingdom Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 258. United Kingdom Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 259. United Kingdom Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 260. United Kingdom Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 261. United Kingdom Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 262. United Kingdom Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 263. United Kingdom Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 264. United Kingdom Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 265. United Kingdom Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 266. Germany Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 267. Germany Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. Germany Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 269. Germany Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 270. Germany Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 271. Germany Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 272. Germany Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 273. Germany Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. Germany Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 275. Germany Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 276. Germany Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 277. France Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 278. France Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 279. France Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 280. France Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 281. France Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 282. France Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 283. France Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. France Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 285. France Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 286. France Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 287. France Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 288. Russia Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 289. Russia Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 290. Russia Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 291. Russia Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 292. Russia Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 293. Russia Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 294. Russia Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. Russia Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. Russia Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 297. Russia Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 298. Russia Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 299. Italy Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 300. Italy Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 301. Italy Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 302. Italy Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 303. Italy Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 304. Italy Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 305. Italy Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 306. Italy Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 307. Italy Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 308. Italy Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 309. Italy Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 310. Spain Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 311. Spain Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 312. Spain Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 313. Spain Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 314. Spain Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 315. Spain Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 316. Spain Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 317. Spain Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 318. Spain Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 319. Spain Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 320. Spain Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 321. China Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 322. China Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 323. China Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 324. China Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 325. China Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 326. China Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 327. China Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 328. China Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 329. China Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 330. China Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 331. China Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 332. India Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 333. India Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 334. India Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 335. India Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 336. India Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 337. India Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 338. India Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 339. India Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 340. India Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 341. India Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 342. India Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 343. Japan Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 344. Japan Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 345. Japan Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 346. Japan Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 347. Japan Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 348. Japan Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 349. Japan Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 350. Japan Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 351. Japan Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 352. Japan Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 353. Japan Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 354. Australia Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 355. Australia Eculizumab Market Size, by Indication, 2017-2032 (USD Million)
TABLE 356. Australia Eculizumab Market Size, by Atypical Hemolytic Uremic Syndrome, 2017-2032 (USD Million)
TABLE 357. Australia Eculizumab Market Size, by Generalized Myasthenia Gravis, 2017-2032 (USD Million)
TABLE 358. Australia Eculizumab Market Size, by Neuromyelitis Optica Spectrum Disorder, 2017-2032 (USD Million)
TABLE 359. Australia Eculizumab Market Size, by Paroxysmal Nocturnal Hemoglobinuria, 2017-2032 (USD Million)
TABLE 360. Australia Eculizumab Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 361. Australia Eculizumab Market Size, by End User, 2017-2032 (USD Million)
TABLE 362. Australia Eculizumab Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 363. Australia Eculizumab Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 364. Australia Eculizumab Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 365. South Korea Eculizumab Market Size, 2017-2032 (USD Million)
TABLE 366. South Korea Eculizumab Market Size, by Indication, 2

Companies Mentioned

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Celltrion Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • UCB S.A.

Related Topics

Related Reports

Complement Inhibitors Market - Global Forecast 2026-2032 - Product Image

Complement Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) Market Report 2026 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2026-2032 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
C5 Complement Inhibitors Market Report 2026 - Product Image

C5 Complement Inhibitors Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Paroxysmal Nocturnal Hemoglobinuria - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 169 Pages
  • Global
From

About the Eculizumab Market

Eculizumab is a monoclonal antibody used to treat hematological diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is a recombinant humanized IgG4 kappa monoclonal antibody that binds to and inhibits the activity of complement component 5 (C5). By blocking C5, eculizumab prevents the formation of the membrane attack complex (MAC), which is responsible for the destruction of red blood cells in PNH and aHUS. Eculizumab is the only approved therapy for PNH and aHUS, and is the only drug that can stop the progression of these diseases. It is administered intravenously, and is typically given once every two weeks. Eculizumab is also being studied for its potential use in other hematological diseases, such as myasthenia gravis and neuromyelitis optica. Companies in the eculizumab market include Alexion Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., and GlaxoSmithKline plc. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.